secwatch.observer — SEC 8-K summary
======================================

Issuer:     PALISADE BIO, INC. (PALI)
CIK:        0001357459
Form:       8-K
Filed at:   2023-02-08T23:59:59+00:00
Accession:  0001493152-23-003966
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 3.02, 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Palisade Bio promotes Robert McRae to COO, appoints J.D. Finley to Board
------------------------------------------------------------------------

- Robert McRae appointed COO effective Feb 2, 2023; previously SVP of Operations and Strategic Development.
- J.D. Finley (interim CEO/CFO) appointed to Board as Class III director, expanding board from 7 to 8.
- Finley's base salary raised to $490K (from $440K) and target bonus increased to 45%, effective Oct 1, 2022.
- Conditional equity grants to officers: 81,500 options ($2.40, 10yr), 59,500 RSUs, 68,700 PSUs; require shareholder approval.
- PSUs vest 50% at $3.20 VWAP and 50% at $4.25 VWAP over 20 consecutive trading days.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1357459/000149315223003966/0001493152-23-003966-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1357459/000149315223003966/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-003966

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer